Passioura, 2005 - Google Patents
Identification of genes with N-ras modulatory function in haematopoietic cellsPassioura, 2005
View PDF- Document ID
- 8656280535818169800
- Author
- Passioura T
- Publication year
External Links
Snippet
Identification of genes with N-ras modulatory function in haematopoietic cells Page 1 Identification
of genes with N-ras modulatory function in haematopoietic cells Author: Passioura, Toby
Publication Date: 2005 DOI: https://doi.org/10.26190/unsworks/6424 License …
- 101710033916 NRAS 0 title abstract description 41
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ren | Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia | |
| Calabretta et al. | The biology of CML blast crisis | |
| Xie et al. | Chronic myelogenous leukemia–initiating cells require Polycomb group protein EZH2 | |
| Scholl et al. | The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis | |
| Gekas et al. | β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1 | |
| Hayashi et al. | Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia | |
| Nitulescu et al. | Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation | |
| Kim et al. | JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias | |
| Lacombe et al. | Genetic interaction between Kit and Scl | |
| Stavropoulou et al. | A novel inducible mouse model of MLL-ENL-driven mixed-lineage acute leukemia | |
| Quere et al. | Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation | |
| Aikawa et al. | Essential role of PU. 1 in maintenance of mixed lineage leukemia‐associated leukemic stem cells | |
| Lynn et al. | C-jun overexpressing CAR-T cells are exhaustion-resistant and mediate enhanced antitumor activity | |
| Nakamura et al. | NF-κB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression | |
| Passioura | Identification of genes with N-ras modulatory function in haematopoietic cells | |
| Mehmetbeyoglu Duman | Imbalance of DNA methylation and demethylation as pathogenic mechanism of acute leukaemia | |
| Belenki | Transcriptional control of cellular plasticity in cancer cell senescence | |
| Van Thillo et al. | Oncogenic cooperation in T-cell acute lymphoblastic leukemia: the role of TLX3 and TCF7-SPI1 | |
| Tonc | Uncovering a MYC-Driven Tumor-Suppressive Program in Proliferating Lymphocytes | |
| Santillan | Functional specificity of the CBP domains in MLL-CBP induced immortalization | |
| Gu | The GAB2/SHP2 Pathway in BCR-ABL1-Induced Hematopoietic Neoplasia | |
| Hasan | JAK2V617F-positive Myeloproliferative Neoplasms: KI mouse models, interferon-α therapy and clonal architecture | |
| Baumeister | Dissecting the role of hypoxia-inducible factor 1 (HIF-1) in JAK2V617F-positive myeloproliferative neoplasms (MPN) | |
| Caeser | Elucidating oncogenic mechanisms in human B cell malignancies | |
| Rafiei | The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia |